Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 18 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

11%

2 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

15Total

Not Applicable (2)

P 1 (7)

P 2 (4)

P 3 (2)

Trial Status

Recruiting6

Unknown4

Completed4

Withdrawn2

Active Not Recruiting2

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 4 completed trials

Clinical Trials (18)

Showing 18 of 18 trials

NCT04406831Recruiting

The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer

NCT05642962Phase 1Active Not Recruiting

Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)

NCT04150042Phase 1Recruiting

SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

NCT03697564Phase 2CompletedPrimary

Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer

NCT07066995Phase 1Recruiting

Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer

NCT03252808Phase 1Active Not Recruiting

Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.

NCT05254171Phase 2Recruiting

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

NCT06518538Phase 2WithdrawnPrimary

Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer

NCT04181645Not ApplicableCompletedPrimary

SHR- 1210 Combined With Paclitaxel (Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer

NCT04674956Phase 3RecruitingPrimary

A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer

NCT06017284Phase 3RecruitingPrimary

Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer

NCT04953962Phase 2CompletedPrimary

Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer

NCT04852367Phase 1Withdrawn

PanDox: Targeted Doxorubicin in Pancreatic Tumours

NCT03412799Phase 1Completed

Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

NCT04628806Unknown

Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells

NCT04137822Unknown

Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer